NAFLD, NASH, MASLD, MASH — Decoding the Name Changes

You're reading an article, and it mentions NAFLD. Then your doctor uses the term MASLD. Your older lab reports say NASH. What's the difference? Are these different diseases? And why can't the medical world just pick one name and stick with it?

The confusion is understandable — and completely justified. In December 2023, after decades of using one set of terms, the global hepatology community voted to change them. The shift wasn't just a rebranding exercise; it reflected a fundamental change in how we understand these diseases. But the change also left patients — and even some healthcare providers — bewildered.

Here's what you need to know: the disease is the same. Your liver is still accumulating fat and inflammation. But the terminology now better reflects what's actually happening and removes the stigma that was baked into the old names.

A Brief History: How We Got Here

The NAFLD Era (1980s–2023)

In the 1980s, researchers noticed that some people had fatty liver disease without significant alcohol consumption. They created a category called "nonalcoholic fatty liver disease" (NAFLD) to distinguish it from alcohol-related liver disease (ARLD).

Within NAFLD, doctors then identified two forms:

• Simple fatty liver — just fat, no inflammation
• NASH (nonalcoholic steatohepatitis) — fat plus inflammation

For 40 years, this terminology dominated. NAFLD and NASH became standard in medical education, research, and patient conversations.

But problems emerged.

The Problems with NAFLD and NASH

Problem 1: Defining by Exclusion

NAFLD literally means "not alcoholic." It's an exclusionary term — it defines the disease by what it's not rather than what it is. That's awkward scientifically and philosophically. It's like defining a disease as "not leprosy" instead of giving it a positive name.

This matters because it creates confusion when a patient has mild alcohol consumption. Do they have NAFLD or ARLD? The boundaries were fuzzy.

Problem 2: Stigmatizing Language

The word "fatty" carries judgment. For patients struggling with weight and metabolic disease, hearing "fatty liver" felt accusatory. The term seemed to blame the patient for moral failings ("you got fat, so your liver is fatty") when the reality is more nuanced — metabolic dysfunction, genetics, insulin resistance, and inflammation are all drivers.

The word "nonalcoholic" also carried an implicit stigma: If you have fatty liver without drinking, it must be your fault — you're fat and sedentary. This wasn't helpful and didn't reflect the science.

Problem 3: Not Capturing the Full Picture

NAFLD and NASH focused on the liver in isolation. They didn't capture that these diseases are fundamentally about metabolic dysfunction — diabetes, insulin resistance, obesity, hypertension, abnormal cholesterol. The names made it sound like a liver problem, when really it's a metabolic problem that happens to damage the liver.

Problem 4: A New Category Emerged

In recent years, researchers recognized another pattern: some people developed fatty liver disease despite minimal metabolic risk factors. They might be lean, have good blood sugar control, and still develop fatty liver. They had alcohol consumption that was more than NAFLD but less than ARLD. The old categories didn't fit.

The 2023 Consensus and New Terminology

In December 2023, a supermajority of over 200 liver experts, public health officials, patient advocates, and industry representatives voted on new terminology. The results were decisive: 75% chose MASLD to replace NAFLD, and 88% chose MASH to replace NASH.

The New Umbrella: Steatotic Liver Disease (SLD)

The new framework uses an umbrella term: steatotic liver disease (SLD) — meaning liver disease characterized by excess fat. Under this umbrella sit several categories:

Metabolic dysfunction-associated steatotic liver disease (MASLD)

• Fat in the liver
• At least one metabolic risk factor (obesity, type 2 diabetes, high blood pressure, abnormal cholesterol, metabolic syndrome)
• Little to no alcohol consumption
• This replaces NAFLD

Metabolic dysfunction-associated steatohepatitis (MASH)

• Fat + inflammation in the liver
• At least one metabolic risk factor
• Little to no alcohol consumption
• This replaces NASH

MetALD (Metabolic and Alcoholic Liver Disease)

• New category for people with metabolic dysfunction who also consume significant amounts of alcohol (140+ g/week for women, 210+ g/week for men)
• Combines the metabolic and alcohol components

Alcohol-related liver disease (ARLD)

• Fat and inflammation driven primarily by significant alcohol consumption
• This category remains largely unchanged

Other steatotic liver diseases

• Viral hepatitis C with steatosis
• Autoimmune hepatitis with steatosis
• Genetic disorders causing steatosis
• Drug-induced steatosis

Why These Changes Matter

Positive naming: MASLD is a positive descriptive term — it tells you what's present (metabolic dysfunction, steatosis) rather than what's absent. That's scientifically cleaner.

Removes stigma: The terms don't blame the patient. They acknowledge the biological reality: metabolic dysfunction is the driver, whether or not the person is overweight.

Captures the whole picture: The term "metabolic dysfunction" acknowledges that this is a systemic metabolic disease, not just a liver problem. It includes insulin resistance, inflammation, lipid abnormalities, and cardiometabolic risk — all of which drive the disease.

Reduces confusion: Clearer categories mean clearer communication between doctors and patients.

Reflects new science: The inclusion of MetALD and other categories reflects our updated understanding that metabolic and alcohol factors can coexist and interact.

What Hasn't Changed

Here's what's critical: the disease is exactly the same. The terminology changed, but the biology didn't.

• Your liver still accumulates excess fat
• Inflammation still develops
• Fibrosis still progresses if untreated
• The risk factors are still the same
• The treatments are still the same
• The interventions (weight loss, metabolic control, lifestyle change) are still the same

If you were diagnosed with NAFLD in 2022, you have MASLD in 2024. It's the same condition with a better name.

The Transition: What You'll See

For the next several years, you'll see mixed terminology:

• Older research papers use NAFLD/NASH
• Newer papers use MASLD/MASH
• Your doctor might use either term (or both) while they adjust
• Insurance systems are slowly updating their coding
• Patient communities are transitioning at different speeds

This is normal and expected. Eventually, MASLD/MASH will become standard, and NAFLD/NASH will fade into medical history (referenced only in older literature).

How to Talk About This with Your Doctor

If your doctor still uses NAFLD, they're not wrong — they're just using older terminology. If you want to be current, you can say: "I've read that this is now called MASLD. Is that what I have?"

If your doctor uses MASLD, they're using the current terminology. Either way, don't get hung up on the labels — the important conversations are about your stage, your risk, and your treatment plan.

What's in a Name?

Language matters. The shift from NAFLD to MASLD represents a shift in how we think about metabolic liver disease:

• From blame to biology
• From exclusion to inclusion
• From liver-centric to metabolic-system perspective
• From stigma to compassion

This might seem like academic hairsplitting, but for patients, the change is meaningful. You're not "fatty" or "nonalcoholic." You have metabolic dysfunction affecting your liver, which is treatable and often reversible. That's a very different story.

What This Means for You

The name change doesn't change anything about your diagnosis or treatment. It doesn't make the disease worse or better. But it does reflect updated science and removes stigmatizing language.

If you were diagnosed with NAFLD:

• That diagnosis is still valid
• You have what's now called MASLD
• All your previous test results and doctor notes remain relevant
• The treatment recommendations haven't changed

Think of it like when meteorologists renamed hurricane categories — the storms didn't get worse or better, but the naming system got clearer and more useful.

How LivaFast Addresses This

LivaFast uses current terminology (MASLD, MASH) in all its content and interface design, reflecting 2023 consensus. But the app doesn't get bogged down in nomenclature — it focuses on what matters: your metabolic health and liver status.

Your Liver Progress Score (LPS) doesn't care what you call the disease. It tracks the metrics that matter:

• Your liver enzyme patterns
• Your metabolic markers
• Your body composition
• Your fasting and metabolic stage

The Doctor Summary PDF export uses current terminology, so when you bring data to your hepatologist, you're speaking the language of modern hepatology.

LiVA, your AI health coach, understands that whether you call it NAFLD or MASLD, your liver responds to the same interventions: metabolic improvement, weight loss, better blood sugar control, reduced inflammation, and increased physical activity.

Key Takeaways

• In 2023, NAFLD was renamed MASLD and NASH was renamed MASH by global consensus.
• The name change reflects science and removes stigmatizing language — the disease itself is unchanged.
• MASLD emphasizes metabolic dysfunction as the driver, not moral failings or simple obesity.
• You might see both old and new terminology for several years as the transition completes.
• Your diagnosis, treatment, and prognosis haven't changed — just the name.
• The most important thing is understanding your stage and taking action — the label matters less than your trajectory.

Sources

1. Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH — PMC/NIH
2. From NAFLD to MASLD: updated naming and diagnosis — PMC/NIH
3. New MASLD Nomenclature — American Association for the Study of Liver Diseases
4. From NAFLD to MASLD: 2023 Brings New Liver Disease Nomenclature — HCPLive
5. Current Update on Nomenclature, Diagnosis, and Management of MASLD — RadioGraphics

---

This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before making changes to your diet or treatment plan.